发明名称 Genetically modified muscle cells which express neurotrophic factors
摘要 An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
申请公布号 US9365828(B2) 申请公布日期 2016.06.14
申请号 US201214002782 申请日期 2012.03.01
申请人 Ramot at Tel-Aviv University Ltd.;Yeda Research and Development Co., Ltd. 发明人 Offen Daniel;Dadon-Nachum Michal;Ben-Zur Tali;Melamed Eldad;Yaffe David
分类号 A01N63/00;A61K48/00;C12N5/077;A61K35/34;A61K35/12;A61K38/00 主分类号 A01N63/00
代理机构 代理人
主权项 1. A method of treating Amyotrophic Lateral Sclerosis (ALS), comprising intramuscularly administering to a subject in need thereof a therapeutically effective amount of the isolated cell population which comprises at least four subpopulations of muscle progenitor cells, each of the at least four subpopulations being distinct in that they are genetically modified to express a different neurotrophic factor, wherein the neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF), thereby treating ALS.
地址 Tel-Aviv IL